Phase i safety and immunogenicity evaluation of mva- cmdr, a multigenic, recombinant modified vaccinia ankara-hiv-1 vaccine candidate

HIGHLIGHTS

• who: Ankara-HIV- et al. from the Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Maryland, United States of America, Mahidol University, Bangkok, Thailand have published the paper: Phase I Safety and Immunogenicity Evaluation of MVA- CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate, in the Journal: (JOURNAL) of November/15,/2010
• what: The authors report here a phase I safety and immunogenicity study with a recombinant MVA-HIV vaccine expressing env/gag/pol inserts derived from a CRF01_AE HIV-1 isolate from Chiang Mai, Thailand, referred to here as MVA-CMDR . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.